| 符小玲,蔡兴权,夏 兰,吴巨峰.血液病患者单采血小板输注疗效的影响因素分析[J].,2018,(16):3167-3169 |
| 血液病患者单采血小板输注疗效的影响因素分析 |
| Analysis of the Influencing Factors for the Clinical Efficacy of Platelet Transfusion in the Treatment of Patients with Hemopathy |
| 投稿时间：2018-02-13 修订日期：2018-03-08 |
| DOI：10.13241/j.cnki.pmb.2018.16.037 |
| 中文关键词: 血液病 单采血小板 输注 疗效 |
| 英文关键词: Hemopathy Apheresis platelets Transfusion Clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 535 |
| 全文下载次数: 293 |
| 中文摘要: |
| 摘要 目的：探讨影响血液病患者血小板输注疗效的因素，为提高血液病患者的临床疗效提供参考依据。方法：选择2013年1月至2015年12月海南省人民医院收治的156例输注单采血小板的血液病患者为研究对象，所有患者单次输入血小板12U(血小板数≥2.5×1011个)，观察输注后血小板计数纠正增加指数(CCI)，分析病种、脾大、发热、年龄、性别对血小板输注疗效的影响。结果：血小板输注总有效率为71.0%。再生障碍性贫血(AA)者血小板输注有效率为65.9%、特发性血小板减少性紫癜(ITP)为65.7%，急性白血病(AL)为77.7%，骨髓增生异常综合征(MDS)为71.9%，不同病种之间血小板输注有效率比较差异无统计学意义(P>0.05)。发热感染者血小板输注有效率为69.9%，明显低于无发热感染者(77.6%，P<0.05)；脾不大者有效率为74.9%，明显高于脾大者(52.86%，P<0.05)；男性、女性有效率分别为76.5%、75.8%，<60周岁者与≧60周岁者有效率分别为72.0%、77.3%，差异均无统计学意义(P>0.05)。随着血小板输注次数的升高，血小板输注无效的发生率也显著升高。结论：发热及脾大是影响血液病患者血小板输注疗效的不利因素。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the influencing factors for the clinical efficacy of platelet transfusion in the treatment of patients with hemopathy. Methods: 156 cases of patients with hemopathy who were treated by platelet transfusion in our hospital from January 2013 to December 2015 were selected. All the patients were given 12 U platelet(≥2.5×1011), the corrected count increment(CCI) after transfusion and the effect of disease category, splenomegalia, fever, age, gender with on the clinical efficacy of platelet transfusion were analyzed. Results: The total effective rate of platelet transfusion was 71.0%, which was 65.9%, 65.7%, 77.7% and 71.9% in patients with aplastic anemia(AA), idiopathic thrombocytopenic purpura(ITP), acute leukemia(AL), myelodysplastic syndrome (MDS) respecctively, no significant difference was found between different disease categories(P>0.05). The effective rate was 69.9% in febrile patients, which was obviously lower than those non-febrile patients(77.6%, P<0.05); the effective rate was 74.9%, which was overtly lower than those with splenomegalia(52.86%, P<0.05); no significant difference was found in the effective rate between male and female, <60 years old and years old(76.5% vs. 75.8%, 72.0% vs. 77.3%)(P>0.05). With the incease of transfusion times, the incidence of platelet transfusion refractoriness was gradually elevated(P<0.05). Conclusion: Splenomegalia and fever were adverse factors for the clinical efficacy of platelet transfusion in the treatment of patients with hemopathy |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
